DR. ROLAND PETER JONES M.D. NPI 1720074610

NPI Details

DR. Roland Peter Jones, M.D. is a pain medicine pain medicine in Tallahassee, FL with 25 years of experience. The provider is pain Medicine is a primary medical specialty based on a distinct body of knowledge and a well-defined scope of clinical practice that is founded on science, research and education. It is concerned with the study of pain, the prevention of pain, and the evaluation, treatment, and rehabilitation of persons in pain. A comprehensive evaluation incorporates the physical, psychological, cognitive and socio-cultural contributions to pain. The treatment protocol may include pharmacological, invasive, behavioral, cognitive, rehabilitative and complementary strategies provided in a concurrent focused and patient specific manner. The pain medicine physician often serves the patient as a frontline physician regarding their pain, but also may serve as a consultant to other physicians, direct an interdisciplinary/multidisciplinary treatment team, conduct research, or advocate for the patient's pain care with public and private agencies. The Pain Medicine physician may work in variety of settings including office, clinic, hospital, university, or governmental/public agencies. DR. Roland Peter Jones, M.D. NPI is 1720074610. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF SOUTH FLORIDA COLLEGE OF MEDICINE
Graduation Year:2000

The provider's business location address is:

1401 OVEN PARK DR
SUITE 201
TALLAHASSEE, FL
ZIP 32308-959
Phone: (850) 765-8623
Fax: (850) 765-0118

The NPI 1720074610 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, onabotulinumtoxina, 1 unit (HCPCS:J0585)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Testing for presence of drug, by chemistry analyzers (HCPCS:80307)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0481)
• Injection, ketorolac tromethamine, per 15 mg (HCPCS:J1885)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, triamcinolone acetonide, not otherwise specified, 10 mg (HCPCS:J3301)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Measurement of brain wave activity (eeg), awake and asleep (HCPCS:95819)
• Injection, midazolam hydrochloride, per 1 mg (HCPCS:J2250)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Injection, fentanyl citrate, 0.1 mg (HCPCS:J3010)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes (HCPCS:99152)
• Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml (HCPCS:Q9966)
• Injection of trigger points, 3 or more muscles (HCPCS:20553)
• Measurement of brain wave activity (eeg), awake and asleep (HCPCS:95819)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, methylprednisolone acetate, 40 mg (HCPCS:J1030)
• Injection, methylprednisolone acetate, 80 mg (HCPCS:J1040)
• Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (HCPCS:G0483)
• Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint (HCPCS:64636)
• Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint (HCPCS:64635)
• Injection of lower or sacral spine facet joint using imaging guidance, single level (HCPCS:64493)

The enumeration date for this NPI number is 9/26/2005 and was last updated on 5/29/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: